Biotechnological company Mesoblast presented positive results of Phase 2 clynical trial accessing use of Mesoblast’s Mesenchymal Precursor Cells (MPCs) in type 2 diabetes patients.
Biotechnological company Mesoblast presented positive results of Phase 2 clynical trial accessed use of Mesoblast’s Mesenchymal Precursor Cells (MPCs) in type 2 diabetes patients at American Diabetes Association annual meeting.
The Phase 2 randomized, single-blind, placebo-controlled, dose escalation trial was conducted across 18 sites in the United States. The trial evaluated the effects of a single intravenous infusion of 0.3, 1.0 or 2.0 million MPCs/kg or placebo over 12 weeks in 61 patients who were inadequately controlled on metformin alone or with one other glucose-lowering agent. Mean diabetes duration was 10 years. Cell drug demonstrated its safety, dose-dependent efficiency in significant reducing of HbA1c level in MPC-treated diabetes patients, decrease of fasting insulin and inflammatory cytokine levels.